Print

China Nuokang Bio-Pharmaceutical Inc. (NKBP) Announces Extraordinary General Meeting of Shareholders  
12/14/2012 9:52:37 AM

BEIJING, Dec. 14, 2012 (GLOBE NEWSWIRE) -- China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) ("Nuokang" or the "Company"), a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products, today announced that it has called an extraordinary general meeting of shareholders (the "EGM"), to be held at 9:30 a.m. (Beijing time) on January 15, 2013, at 26th Floor, Gloucester Tower, The Landmark, 15 Queen's Road Central, Hong Kong, to consider and vote on, among other things, the proposal to authorize and approve the previously announced agreement and plan of merger (the "Merger Agreement") dated September 27, 2012, among the Company, Kingbird Investment Inc. ("Parent") and Kingbird Mergerco. Inc. ("Merger Sub"), and, solely for the purposes of Section 6.16 thereof, Anglo China Bio-technology Investment Holdings Limited and Britain Ukan Technology Investment Holdings (Group) Limited, and the plan of merger required to be filed with the Registrar of Companies of the Cayman Islands, substantially in the form attached as Exhibit A to the Merger Agreement (the "Plan of Merger") and the transactions contemplated thereby (including the merger).
//-->